ANAPTYSBIO INC
SAN DIEGO, CA · Founded 2005 · CIK 0001370053 · Biotech · Public
Biopharmaceutical development and drug candidates (in collaboration with GSK and Vanda)
anaptysbio.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $51M
- 5 Form D · Jul 2015
- 135 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 16 granted · 24 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2010201120122013201420152016
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $9,600 | |
| Private capital raised | Form D · SEC | $14,400 | |
| Private capital raised | Form D · SEC | $8,024,394 | |
| Private capital raised | Form D · SEC | $2,022,117 | |
| Private capital raised | Form D · SEC | $40,767,277 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2893 | Santa Ana Bio, Inc. | — | $63M |
| 2894 | General Specific Inc. | — | $1.5M |
| 2895 | Character Biosciences, Inc. | — | $57M |
| 2896 | ANAPTYSBIO INC | — | $51M |
| 2897 | Graywolf Therapeutics | — | — |
| 2898 | Beeline Medicines | — | — |
| 2899 | GENERATION BIOTECH, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Tiba AynechiDirector
- Carol GallagherDirector
- Robert HoffmanExecutive Officer
- Kevin KinsellaDirector
- Marco LondeiExecutive Officer
- Heath LukatchDirector
- Heathe LukatchDirector
- Nicholas LydonDirector
- Nick LydonDirector
- J. ReadDirector
- Hollings RentonDirector
- John SchmidDirector
- Thomas SmartDirector · Executive Officer
- Hamza SuriaDirector · Executive Officer
- James TopperDirector
Patents
- Method Of Treating Ichthyosis In A Subject By Administering An Anti-interleukin 36 Receptor (IL-36R) Binding Agentgranted
- Antibodies Directed Against Interleukin 36 Receptor (IL-36R)application
- B And T Lymphocyte Attenuator (btla) Modulators And Method Of Using Sameapplication
- Antibodies Directed Against Interleukin 36 Receptor (IL-36R)granted
- Antibodies Directed Against INTERLEUKIN-33 (IL-33)application
- Antibody Compositionapplication
- Method Of Treating Autoimmune Disease With Antibodies Against IL-33granted
- Antibody Agents Directed Against Lymphocyte Activation Gene-3 (LAG-3) and Uses Thereofapplication
- Anti-interleukin 36 Receptor (IL-36R) Therapy For Hidradenitis Suppurativaapplication
- B And T Lymphocyte Attenuator (btla) Modulators And Method Of Using Sameapplication
- Antibodies Directed Against Programmed Death-1(PD-1)application
- Method Of Treating Ichthyosis In A Subject By Administering An Anti-interleukin 36 Receptor (IL-36R) Binding Agentapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.